NCT05137093已完成不适用
Independent Validation Study of Nighttime Scratching Quantification With Actigraphy in Adults With Atopic Dermatitis
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 27
- 试验地点
- 1
- 主要终点
- Sensitivity and precision of the scratching algorithm with reference to the gold standard.
研究概览
简要总结
Single center, analyst-blinded, study comparing the scratching events identified via an actigraphy scoring algorithm versus manual scoring of an overnight video recording, undertaken in a sample of 40 adult patients with atopic dermatitis and controls.
详细描述
The Philips scratching algorithm has been cross-validated against the gold-standard assessment of scratching. The algorithm has been used in many drug development trials, occasionally as a means of generating secondary endpoints, but most often as a means of generating exploratory endpoints. The purpose of the proposed study is therefore to validate the data generated by the scratching study compared to the gold-standard video-assessment of scratching, in an independent sample of adults with atopic dermatitis and age- and sex-matched controls
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Be aged 18 to 75 years, inclusive
- •Be willing and able to undergo a single night of actigraphy and video monitoring overnight in a laboratory
- •Be willing and able to provide informed consent
- •(patients only): Diagnosed with atopic dermatitis by a clinician, following the criteria listed in Table
- •(patients only): IGA score ≥
- •(patients only): Willing and able to use only non-medicated topical therapy (i.e., bland emollient/moisturizer) for 7 days before the overnight visit.
- •Participants should be in bed a minimum of 4 hours
排除标准
- •Any acute and/or unstable illness or medical complication which, in the opinion of a clinician, could compromise data collection and/or interpretation
- •Use of any over-the-counter, prescription, or recreational drugs that may induce sleep or pruritus within 24 hours prior to overnight monitoring
- •Use of any over-the-counter or prescription treatment (systemic, or topical) that could affect the course of atopic dermatitis during the study period. Key medications are listed below:
- •From 3 Months prior to overnight visit: Biological products that might have significantly affected the evaluation of atopic dermatitis condition (e.g., tumor necrosis factor inhibitors, antiimmunoglobulin IgE antibodies, anti-CD20 antibodies, anti-interleukin-4 receptor)
- •Has used systemic treatments that could affect AD within 30 days or 5 half- lives before the overnight visit. (i.e. retinoids, methotrexate, cyclosporine, hydroxycarbamide (hydroxyurea), azathioprine and systemic corticosteroids)
- •Phototherapy treatment, laser therapy, bleach baths, tanning booths or extended sun exposure that could affect disease severity or interfere with disease assessments within 30 days before the overnight visit.
- •Use within 21 days before the overnight visit: Topical corticosteroids that were classified as super-high potency (clobetasol propionate).
- •Use within 14 days before the overnight visit: any other topical phosphodiesterase 4 (PDE4) inhibitor; Tacrolimus and pimecrolimus cream and/or ointment; Topical corticosteroids that were classified as low, medium, or high potency (e.g., fluocinonide, triamcinolone acetonide, desonide, hydrocortisone).
- •From 7 days before the overnight visit:
- •antibiotics
- •antifungal or antivirus medications
- •Antihistamines/anti-allergics: diphenhydramine, chlorpheniramine maleate, hydroxyzine)
- •Topical phosphodiesterase 4 (PDE4) inhibitor
- •Topical calcineurin inhibitors (tacrolimus and pimecrolimus cream and/or ointment)
- •Topical corticosteroids that were classified as low, medium, or high potency (e.g., fluocinonide, triamcinolone acetonide, desonide, hydrocortisone)
- •Any other topical therapy with active ingredients to treat AD or with additives that could affect AD (e.g., hyaluronic acid, urea, ceramide or filaggrin degradation products).
- •Individuals clinically diagnosed with a sleep disorder who are NOT on a controlled treatment regime
- •An Epworth Sleepiness Scale score of ≥11, indicating daytime hypersomnolence
- •Previous diagnosis of a movement disorder, including but not limited to, restless legs syndrome, periodic limb movement disorder, Tourette's syndrome, tremor, or dystonia
- •Commercial driver's license and/or high-risk occupation that could be impacted by the occurrence of daytime sleepiness
- •Self-reported habitual sleep duration of <6 hours per night on average
- •Shift worker, advanced/delayed circadian phase, and/or any other condition suggesting that the participant would be unable to sleep during overnight monitoring
- •Self-reported pregnancy current or planned during the study
- •Employee or spouse of an employee of company that designs, sells, or manufactures sleep related products and/or wearable devices (including Philips).
- •(patients only): Any significant dermatological condition, other than atopic dermatitis, as determined by a clinician.
- •(controls only): Any significant dermatological condition as determined by a clinician.
- •Currently using medication for any skin disease/condition and could not, in the opinion of the investigator, tolerate restriction or discontinuation of the medication as required by the study.
结局指标
主要结局
Sensitivity and precision of the scratching algorithm with reference to the gold standard.
时间窗: Through study completion, analyst review following each patient's overnight intervention/session
Assessment of the performance of the scratching algorithm as detected by actigraphy compared to infra red video monitoring.
次要结局
- Agreement via additional performance metrics between the scratching algorithm and the gold standard.(Through study completion, analyst review following each patient's overnight intervention/session)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Wearable Skin Sensors to Assess Nocturnal Scratch BehaviorAtopic DermatitisNCT03770858Northwestern University23
尚未招募
不适用
Assessment of nocturnal scratching activity in atopic dermatitis patients with scratching-detecting deviceAtopic dermatitisJPRN-UMIN000024665estle Skin Health S.A.35
已完成
不适用
A Study to Assess the Reliability/Feasibility of Using Emerald Touchless Sensor for Scratching and Sleep Quantification in a Subset of Participants From PEDISTAD Study (OBS15333; NCT03687359)Dermatitis AtopicNCT05235724Sanofi18
终止
4 期
Improvement In Scratch Behavior And Sleep In Patients With Atopic DermatitisAtopic DermatitisNCT05200403Boston University72
已完成
Unknown
Contracture management in Duchenne muscular dystrophyDuchenne muscular dystrophyISRCTN18436655ewcastle upon Tyne Hospitals NHS Foundation Trust5